Hemab adds Keli Walbert to board and audit committee without advancing pipeline

Hemab is a clinical-stage biotech building a rare-bleeding-disorder pipeline around sutacimig, HMB-002, and earlier-stage HMB-003 programs. The filing adds governance capacity, not operating momentum. The board elected Keli Walbert effective immediately and placed her on the Audit Committee. 〔0〕 〔1〕 That may improve oversight as Hemab manages clinical development and public-company reporting, but it does not change a drug program, trial timeline, cash position, or regulatory path.

The economic impact is routine and modest relative to the company's development stage. Walbert receives $40,000 annually for board service plus $10,000 for Audit Committee work, along with a 36,000-share option that vests over three years. The option creates some dilution potential, but the filing provides no share-count context or indication that this is material to the broader financing story.

Bottom line: This is a new but routine governance addition. It modestly strengthens oversight while leaving Hemab's core clinical and funding narrative essentially untouched.